

Area Drugs and Therapeutics Committee Meeting Agenda

Wednesday 22nd October 2025 10-12.30pm

Microsoft Teams Meeting

	Present	
	Graeme Bryson (Chair) David Semple Victoria Gemmell (Prof Sec) Kelly Baillie (Item 12) Gail Richardson Kavan Stafford Rachael Kelly Chris Miller Kirsty Macfarlane Craig Thurtell Penny Brankin Stephanie Dundas Tyra Smyth Kaven Stafford Rebecca Ritchie/Michelle Spittal (Item 15) Sarah Brady (Item 8e) Emma Harris (Item (14))	
	Quorate-6 members. Y	
1.	Apologies for Absence	
	Sharon Murray, Veronica Rainey, Colin Angus	
2.	Declaration of Interest	
	Nil	
3.	Ratification of minutes of September 2025 meeting	
	These were accepted as a true reflection of the meeting and can be published.	
4.	Matters arising not covered elsewhere on the agenda	
	a. Adult Non Obstetric Major Haemorrhage – Andrew Fyfe (For noting) This was approved. b. Produodopa Clinical Protocol – Eimear Gordon This will be carried over to November meeting. c. Chest Wall Injury Analgesia Pathway – Kathryn Bennet This was approved. d. R-hGH Guideline – Ian Hunter Update Awaited e. Elafibranor – Sean Haughey Update Awaited f. Cabotegravir – Alison Currie Unable to open embedded doc. This was approved. g. Protocol for Administration of Warfarin by Community Nursing in Primary Care – Christine Paterson Update Awaited h. SLWG Bariatric Conclusion Paper – James Torrens Update Awaited i. CMP Pathway for Primary Care – James Torrens Update Awaited j. Peripheral Non-Adrenaline – Nicholas Holt Update Awaited	

Area Drugs and Therapeutics Committee Meeting Agenda

Wednesday 22nd October 2025 10-12.30pm

Microsoft Teams Meeting

5.	ADTC Committee Business	
	<p>a. Draft ToR – Veronica Rainey - Final version for approval Approved subject to minor amendments.</p> <p>b. Declaration of Interest Document & Guidance – Graeme Bryson These will be produced in due course.</p>	
6.	SMC Advice - CONFIDENTIAL	RK
6.1	SMC Advice – October 2025 These were noted.	
6.2	<p>Updates to NHS LK status on SMC advice RK outlined proposed updates in designations for SMC medicines and NCMAG advice. This was agreed. Advice for new SMC medicines which are set to or have breached the board decision deadline are as noted in the follow up document.</p>	
6.3	<p>Updates to Lanarkshire Bulletins These were agreed. Post-meeting note: SMC numbers of which board decision exceeded the deadline confirmed as SMC2649, SMC2723 and SMC2698.</p>	
6.4	<p>Outstanding SMC New Medicines Decisions Nil</p>	
7.	Lanarkshire Formulary / West of Scotland Formulary	TBC
7.1	<p>NHSLK formulary changes proposals RK presented proposed formulary amendments which were approved. This included updated wording within the relevant sections to further highlight the NHS Lanarkshire eligibility criteria for specific therapies for weight management, updates to the medicines listed for treating Multiple Sclerosis, a subsequent update to remove some dosing information for vaginal oestrogen, and general formatting updates.</p> <p>Asthma – formulary amendments in line with updated NHS Lanarkshire guideline ‘Pharmacological Management of Adult Asthma in Primary and Secondary Care’ (May 2025).</p> <p>Formulary Amendment Form, Blood Glucose Test Strips – This detailed amendments to formulary choices due to discontinuations of certain blood glucose monitors.</p> <p>Formulary Amendment Form, Chlorhexidine Hibiwash/Hibiscrub – This form was amended following Committee feedback and proposed an update to list this medicine generically on the formulary.</p>	
7.2	<p>West of Scotland Formulary Updates KM gave an update on progress with the Regional Formulary.</p> <p>a. WoS Formulary – Nominations for Formulary Committee</p>	

Area Drugs and Therapeutics Committee Meeting Agenda

Wednesday 22nd October 2025 10-12.30pm

Microsoft Teams Meeting

	A request was made for nominations for RF Committee. It was agreed that it is important for NHSL to participate in RF decision making. WoS Directors will be considering plans for GP participation in due course.	
8.	Clinical Protocols & Guidelines	
	<p>a. Gestational Diabetes Mellitus (GDM) – James McClaren The clinical content was agreed as helpful and useful, however a number of points require amending or clarification. This was not approved.</p> <p>b. Prescribing Guidelines for the provision of Medication Assisted Treatment (MAT) – Duncan Hill (For noting) This was approved.</p> <p>c. Abdominal Wound Catheter Local Anaesthetic Top up Protocol – Colum Slorach A number of points require amending or clarification. The guideline was not approved.</p> <p>d. Lipid Clinic for High Risk Stroke Patients – A number of points require amending or clarification. The guideline was not approved.</p> <p>e. Serotonin Syndrome – Sarah Brady * This is an amalgamation of existing guidance, with a number of updates. Approved subject to changes.</p> <p>f. Pre-term Birth (Intact Membranes) – Gordon Buchanan Approved pending small changes</p> <p>g. Vibegron – Claudia Fede Spicchale Approved with no changes</p> <p>h. Abaloparatide - Zhuo Min Chong * Carried over to next meeting</p> <p>i. Osteoporosis Guideline – Zhuo Min Chong * Carried over to next meeting</p> <p>j. Mavacamten – Robin Weir A number of points require amending or clarification. The guideline was not approved.</p> <p>k. Preoperative Management of GLP-1 Agonists – Emma Murphy A number of points require amending or clarification.</p>	

Area Drugs and Therapeutics Committee Meeting Agenda

Wednesday 22nd October 2025 10-12.30pm

Microsoft Teams Meeting

	<p>The guideline was not approved.</p> <p>I. Pruritus Following Neuraxial Opiate Administration in Obstetric Patients – Maciej Dalidowski This was a review of an existing guideline. Approved subject to minor amendments</p>	
BREAK (10 Minutes)		
9.	ULM Requests	
	<p>a. Blanket ULM - Lidocaine – Ruth Waters This was approved.</p>	
10.	New Medicine Safety Notifications & Alerts	
	<p>a. CAS - Home https://www.gov.uk/drug-safety-update</p> <p>b. MHRA Safety Roundup – September 2025 MHRA Safety Roundup: September 2025 - GOV.UK This was noted.</p>	
11.	Prescribing Management Board Update	GRB
	Development of these are progressing.	
12.	Medicines for the Treatment of Cancer	KB
	<p>PASG – Summary paper KB gave an update on advice from the Regional Prescribing Advisory Group. ADTC was assured by progress on SMC advice implementation and regional guidance. Noted some 90-day breaches with plans in place.</p>	
13.	Non-Medical Prescribing	
	Nil	
14.	PGD Activity Report	RK
	<p>a. Palliative Care Grab Bags – Emma Harris * EH gave a summary. It was noted that systems put in place regarding the use of “grab bags” containing a selection of medicines for use in EOL care was implemented during the COVID pandemic using PGD’s. These are approaching expiry and it is acknowledged that this system may no longer be appropriate. A SLWG has been convened to review and make recommendations as to future plans, and the PGD’s require an extended expiry to facilitate this. There were a variety of comments regarding the necessary duration of this. ADTC was supportive of an extension, and notes the PMMB position on this, however there was no consensus on the duration of the extension. It was agreed that continued evidence of progress with the SLWG would provide assurance. This will be fed back to the signatories.</p>	

Area Drugs and Therapeutics Committee Meeting Agenda

Wednesday 22nd October 2025 10-12.30pm

Microsoft Teams Meeting

	<p>b. September 2025 PGD Activity Report RK gave a summary, highlighting specific PGDs where discussions are ongoing to progress to organisational approval. The report was presented with a verbal update around potentially expired emergency department PGDs. This report was accepted by the committee as reassurance of appropriate governance structures.</p>	
15.	Antimicrobial Management Team Update	SD
	<p>a. Ceftriaxone administration SBAR - Rebecca Ritchie * RR gave a summary. The OPAT service administer IV medicines following advice published by Mesdusa. Due to changes in the monograph for administration of higher dose ceftriaxone, current practice may need to change from IV infusion to double IV bolus. The ask of the committee is to endorse an updated method of administration following advice from the manufacturer instead of Medusa. Comments from the committee noted potential safety risks of bolus injections, compared to infusion, versus potential infection risk and convenience and cost. The committee did not feel sufficiently reassured at this time and so the recommended that current practice should continue.</p> <p>b. Diabetic Foot Infection Guideline – Gary Lynas This was approved.</p>	
16.	Lay member related items	
	Nil	
17.	Correspondence	
	<p>a. ADTCC Terms of Reference These were noted.</p> <p>b. Removal of Guidelines from Firstport Work on this is progressing.</p>	
18.	AOCB	
	Nil	
19.	Date of Next Meeting	
	Wednesday 19 th November 2025 10-12.30pm Via MS Teams	